Details for Patent: 8,829,017

Which drugs does patent 8,829,017 protect, and when does it expire?

Patent 8,829,017 protects XIFAXAN and is included in one NDA.

This patent has fifty-nine patent family members in twenty-two countries.

Summary for Patent: 8,829,017

Title:	Methods of treating traveler's diarrhea and hepatic encephalopathy
Abstract:	Treatment of traveler's diarrhea using in subjects having hepatic encephalopathy using gastrointestinal specific antibiotics is disclosed. One example of a gastrointestinal specific antibiotic is rifaximin.
Inventor(s):	William Forbes, Enoch Bortey
Assignee:	Salix Pharmaceuticals Ltd
Application Number:	US13/076,967
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,829,017
Patent Claim Types: see list of patent claims	Use; Dosage form;

Drugs Protected by US Patent 8,829,017

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Salix Pharms	XIFAXAN	rifaximin	TABLET;ORAL	021361-002	Mar 24, 2010	AB	RX	Yes	Yes	8,829,017					TREATMENT OF PATIENTS WITH HEPATIC ENCEPHALOPATHY (HE)

International Family Members for US Patent 8,829,017

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2009298389
Australia	2010260089
Australia	2010271070
Brazil	PI0920465
Brazil	PI1010028